Tag: Cyclophosphamide
Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials have favored the use of cyclophosphamide (CYC) for treating SSc-ILD3,4,5. Compared with placebo, 1 year of CYC improved lung function in patients with SSc-ILD in Scleroderma Lung Study (SLS) I3
01.04.2019